|1.||Pisano, Claudio: 7 articles (09/2014 - 03/2003)|
|2.||Carminati, Paolo: 5 articles (03/2007 - 03/2003)|
|3.||Zuco, Valentina: 4 articles (03/2011 - 03/2003)|
|4.||Zunino, Franco: 4 articles (03/2011 - 03/2003)|
|5.||D'Incalci, Maurizio: 3 articles (08/2012 - 03/2007)|
|6.||Zunino, F: 3 articles (09/2007 - 03/2004)|
|7.||Pisano, C: 3 articles (09/2007 - 03/2004)|
|8.||Merlini, Lucio: 3 articles (09/2006 - 03/2003)|
|9.||Riccardi, Riccardo: 2 articles (08/2012 - 03/2007)|
|10.||Torella, Anna Rita: 2 articles (08/2012 - 03/2007)|
03/01/2010 - "Indeed, in this study performed in ovarian carcinoma cells, we show that exposure to ST1926 resulted in an increase of early markers of DNA damage, including ATM and H2AX phosphorylation. "
09/01/2007 - "The novel adamantyl retinoid ST1926 is a potent inducer of apoptosis in ovarian carcinoma cells. "
07/01/2005 - "To better understand the relevance of these events, we have selected a subline of the H460 lung carcinoma cell line resistant to ST1926. "
03/01/2004 - "Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid."
03/01/2010 - "In addition, we found that a novel histone deacetylase (HDAC) inhibitor (RC307) was able to enhance sensitivity of ovarian carcinoma cells to ST1926. "
08/01/2015 - "Most importantly, oral treatment with ST1926 significantly prolonged the longevity of primary CML mice, and reduced tumor burden. "
09/01/2007 - "In contrast to the marginal effect of ST1926 alone against the subcutaneous-growing tumors, loco-regional (intraperitoneal) treatment achieved a marked increase of survival of animals with ascitic IGROV-1 tumor. "
03/01/2007 - "Overall, our results support the view that ST1926 might represent a good drug candidate in this pediatric tumor."
03/13/2003 - "The novel atypical retinoid E-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926, 4) exhibited a potent antiproliferative activity on a large panel of human tumor cells. "
03/01/2007 - "In vivo, orally administered ST1926, appeared to inhibit tumor growth of NB xenografts with tolerable toxicity. "
|3.||Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
|4.||Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
03/01/2007 - "This study aims at investigating the antitumor activity of ST1926 in neuroblastoma (NB) preclinical models. "
08/01/2012 - "Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models."
03/01/2007 - "The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism."
08/01/2012 - "In the present study, we show that retinoic acid enhances the cytostatic and apoptogenic properties of the novel adamantyl retinoid ST1926 in a panel of neuroblastoma cells with different p53 status and caspase 8 expression, resulting in synergistic effects as assessed by Combination Index and Isobologram analysis. "
|2.||Histone Deacetylase Inhibitors
|5.||Caspase 8 (Caspase-8)
|6.||Tretinoin (Retinoic Acid)
|8.||Histone Deacetylases (Histone Deacetylase)
|9.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)